Cartesian Therapeutics (RNAC) Interest Expenses (2015 - 2023)

Cartesian Therapeutics (RNAC) has 9 years of Interest Expenses data on file, last reported at $1.3 million in Q3 2023.

• Interest Expenses for Q3 2023 came in at $1.3 million, up 58.73% year-over-year; the trailing twelve-month figure through Jun 2024 was $1.3 million (down 59.83% YoY), and the FY2023 annual result was $2.8 million, down 6.53% from the prior year.
• Interest Expenses grew to $1.3 million in Q3 2023 per RNAC's latest filing, from $752000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $1.3 million in Q3 2023 and troughed at $205000.0 in Q2 2020.
• A 5-year average of $620157.9 and a median of $711000.0 in 2021 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2019 and 2020: Interest Expenses surged 5683.33% in 2019, then tumbled 48.75% in 2020.
• A 5-year view of Interest Expenses shows it stood at $335000.0 in 2019, then surged by 112.84% to $713000.0 in 2020, then slipped by 0.28% to $711000.0 in 2021, then grew by 13.5% to $807000.0 in 2022, then soared by 57.74% to $1.3 million in 2023.
• Business Quant data shows RNAC's Interest Expenses at $1.3 million in Q3 2023, $752000.0 in Q2 2023, and $808000.0 in Q1 2023.